US Corporate Board Director Changes SEC Filings — March 09, 2026

09-03-2026

On March 6, 2026, Phillips 66's Board of Directors increased its size from 14 to 16 members and appointed Kevin O. Meyers (age 72) and Howard I. Ungerleider (age 57) as independent directors, effective immediately. Meyers was assigned to the class expiring in 2027 and Ungerleider to the class expiring in 2026; both joined the Audit & Finance Committee and Public Policy and Sustainability Committee. In connection, Grace Puma Whiteford was reclassified as a Class I director with term expiring in 2028.

• ·No arrangements or understandings for appointments; no material interests under Item 404(a) of Regulation S-K.
• ·Pro-rated compensation per standard non-employee director arrangements described in April 8, 2025 proxy statement.

09-03-2026

Boundless Bio reported Q4 and FY 2025 financial results with reduced R&D expenses (Q4: $9.8M vs $13.3M YoY, -26%; FY: $44.8M vs $55.3M, -19%) and net losses (Q4: $12.9M vs $16.4M, -21%; FY: $58.2M vs $65.4M, -11%), alongside a $108M cash position providing runway into H2 2028. The company opened enrollment in the KOMODO-1 trial for BBI-940 after FDA IND acceptance, but announced cessation of enrollment in the POTENTIATE trial of BBI-355 and BBI-825 due to prioritization. Cash decreased to $107.6M from $152.1M at end-2024.

• ·Total operating expenses Q4 2025: $14.0M vs $18.3M Q4 2024 (-23%)
• ·Total operating expenses FY 2025: $63.6M vs $73.3M FY 2024 (-13%)
• ·Net loss per share FY 2025: $(2.60) vs $(3.85) FY 2024
• ·Accumulated deficit as of Dec 31, 2025: $259.7M (up from $201.5M at end-2024)
• ·Working capital as of Dec 31, 2025: $97.1M (down from $146.3M at end-2024)

09-03-2026

Fluor Corporation's Executive Chairman David E. Constable announced his retirement effective May 6, 2026, coinciding with the annual stockholders' meeting, with James T. Hackett appointed as the new Board Chair effective May 5, 2026. The company entered a one-year consulting agreement with Constable for $525,200, payable quarterly starting May 6, 2026. The Board also expanded to 12 members and elected independent director Robert G. Card, assigning him to the Audit Committee and Commercial Strategies and Operational Risk Committee.

• ·Board elected Robert G. Card effective March 4, 2026; determined independent under NYSE standards.
• ·Consulting agreement dated March 4, 2026; full text to be filed in Q1 2026 10-Q.
• ·Annual stockholders' meeting scheduled for May 6, 2026.

09-03-2026

Ionis Pharmaceuticals announced that long-serving directors B. Lynne Parshall (since September 2000) and Joseph Wender (since January 1994, lead independent director since 2020) will retire at the end of their terms on June 4, 2026. Peter N. Reikes will rejoin the Board effective the same date, bringing expertise from recent roles at ARPA-H and FDA, as well as prior investment banking positions at Stifel, Cowen, and PaineWebber. The changes reflect planned transitions amid the company's growth, with no immediate disruptions noted.

• ·Parshall served as COO (Dec 2007-Dec 2017) and CFO (Jun 1994-Dec 2012)
• ·Wender joined Goldman Sachs in 1971, general partner in 1982, senior consultant since Jan 2008
• ·Reikes: Senior strategy advisor at ARPA-H (Dec 2024-Feb 2026), FDA senior advisor (prior 3+ years), previously Ionis director (2018-2021)
• ·Reikes education: B.A. Economics (UCLA), M.B.A. Finance (Wharton)

09-03-2026

Gulfport Energy Corporation announced the immediate departure of John Reinhart as President, CEO, and Director, potentially introducing leadership uncertainty. An Office of the Chairman has been established, led by Timothy J. Cutt (Chairman and former CEO) alongside executives Michael Hodges (CFO), Matthew Rucker (COO), and Patrick Craine (Chief Legal and Administrative Officer), with a search firm retained for a new CEO. The company emphasized that its 2026 development plan, strategy, and commitment to free cash flow and shareholder returns remain unchanged.

• ·Principal properties in eastern Ohio (Appalachia basin) and central Oklahoma (Anadarko basin)
• ·Investor contact: jantle@gulfportenergy.com, 405-252-4550

09-03-2026

FTI Consulting, Inc. (NYSE: FCN) elected Angela Nam as Chief Financial Officer effective May 1, 2026, succeeding Paul Linton who served as Interim CFO since September 2025 and will return to his role as Chief Strategy and Transformation Officer. Ms. Nam brings extensive experience, including leading FTAI Aviation Ltd. (NASDAQ: FTAI) through significant growth with revenues increasing from $708M in 2022 to $2.5B in 2025. The company reported $3.80B in FY 2025 revenues and more than 8,100 employees across 32 countries as of December 31, 2025.

• ·Angela Nam previously served as CFO and CAO of FTAI Aviation since August 2022 (CAO from August 2018), Senior VP of Private Equity at Fortress Investment Group, and 10 years at KPMG LLP.
• ·Ms. Nam will be based in FTI's New York City office and serve on the Executive Committee.
• ·FTI services provided through distinct legal entities in certain jurisdictions.

09-03-2026

Gokul Rajaram informed The Trade Desk, Inc. of his resignation from the board of directors on March 3, 2026, effective April 3, 2026; the resignation was not due to any disagreement with the company's operations, policies, or practices. Mr. Rajaram had served on the board since May 2018. The board thanked him for his years of service.

• ·Filing dated March 9, 2026

09-03-2026

On March 5, 2026, Alpha and Omega Semiconductor Limited's Compensation Committee approved an incentive cash bonus plan for the 2026 calendar year, tying executive officer awards to attainment of adjusted earnings per share and revenue goals, with minimum thresholds required for any payout. Bonuses range from $0 to maximums as a percentage of base salary: 220% target for CEO Stephen Chang (target 100%) and 154% for other named executives (target 70%). The full plan details will be filed as an exhibit to the Q1 FY2026 10-Q ending March 31, 2026.

• ·Plan qualified in entirety by full details to be filed in 10-Q for quarter ending March 31, 2026
• ·Aggregate award determined by range of adjusted EPS and revenue attainment levels

09-03-2026

Nu Skin Enterprises Inc. (NYSE: NUS) appointed Chayce Clark as chief operating officer effective March 9, 2026, expanding his responsibilities from chief legal officer to oversee revenue performance, global sales, product innovation, technology platforms, and operations across nearly 50 markets. CEO Ryan Napierski highlighted the move to enhance global integration and execution amid growth opportunities like the Prysm iO platform rollout and India expansion. No financial impacts or performance metrics were disclosed in the announcement.

• ·Chayce Clark joined Nu Skin in 2015 as assistant general counsel, progressed to VP and deputy general counsel, then general counsel.
• ·Nu Skin backed by over 40 years of scientific research.

09-03-2026

Shift4 Payments, Inc. announced that Chief Accounting Officer James (“Jay”) Whalen will resign effective April 3, 2026, to accept a position outside the fintech industry, with no disagreements on operations, policies, or practices. CFO Christopher N. Cruz will be designated as principal accounting officer, and Filippos Mintiloglitis will serve as interim Chief Accounting Officer. CEO Taylor Lauber expressed confidence in the transition, citing the strength of the accounting team and Mintiloglitis's expertise from leading public reporting at Global Blue amid its integration.

• ·Event reported on March 3, 2026; filing dated March 9, 2026.
• ·Whalen's departure not due to any disagreement with Company operations, policies, or practices.
• ·Mintiloglitis brings technical expertise and international experience from Global Blue.

09-03-2026

The RealReal, Inc. announced the appointment of Jennifer McKeehan, COO of Fanatics Commerce, to its Board of Directors effective March 6, 2026, following the departure of Niki Leondakis from her board role on the same date. The company also added Tiffany Stevenson as Chief People Officer and Tom Hanrahan as Chief Revenue Officer to its executive leadership team. These changes are positioned to enhance governance, operational expertise, and growth strategies in luxury resale.

• ·McKeehan previously held senior roles at Walmart, Peloton, and The Home Depot.
• ·Stevenson previously at Weight Watchers, Box, and Sephora.
• ·Hanrahan spent 11 years at Square in executive roles.
• ·Changes effective March 6, 2026; filing dated March 9, 2026.

09-03-2026

On March 6, 2026, Mathew Tirman, President of Satellogic Inc., notified the company of his voluntary resignation effective March 31, 2026, to pursue other opportunities, with no severance benefits provided. The company has no immediate plans to fill the role and intends to distribute his duties among other executives. This departure occurs amid the company's status as an emerging growth company with Class A Common Stock (SATL) and Warrants (SATLW) listed on Nasdaq Capital Market.

• ·Company address: 210 Delburg Street, Davidson, NC 28036
• ·Telephone: (704) 802-2041
• ·Satellogic Inc. is an emerging growth company
• ·Securities: Class A Common Stock (SATL) and Warrants (SATLW) on Nasdaq Capital Market

09-03-2026

James E. Schisler, Chief Operating Officer of The Brand House Collective, Inc. (TBHC), announced his intent to resign effective March 20, 2026, to pursue other opportunities, with no disagreements with the Company. He will remain in his role until the departure date. The resignation was announced on March 4, 2026, with the 8-K filed on March 9, 2026.

• ·Principal executive offices: 5310 Maryland Way, Brentwood, Tennessee 37027
• ·Telephone: 615-872-4800
• ·Common Stock trading symbol: TBHC on NASDAQ Global Select Market

09-03-2026

West Pharmaceutical Services, Inc. (NYSE: WST) announced that Eric M. Green plans to retire as President, CEO, and Chair of the Board once a successor is hired, with the transition expected in the second half of 2026 to ensure continuity. The Board commended Green's 11-year tenure since April 2015, during which company sales more than doubled and total shareholder return achieved approximately 350%. The company reaffirmed its prior financial guidance, noting FY2025 net sales of $3.07B, over 10,000 team members across 50 sites, and annual delivery of over 41 billion components and devices.

• ·Eric M. Green served as President and CEO since April 2015 and Chair since May 2022.
• ·Board engaging leading executive recruiting firm for successor search.
• ·Guidance reaffirmed from February 12, 2026 press release.

09-03-2026

Planet Fitness, Inc. (PLNT) announced Tom Fitzgerald, former CFO from 2020-2024, as Interim CFO effective March 9, 2026, following Jay Stasz's departure, with a search initiated for a permanent CFO. The company reaffirmed its 2026 financial guidance previously issued on February 24, 2026. No disruptions to operations or guidance noted, highlighting Fitzgerald's extensive experience.

• ·Planet Fitness founded in 1992 in Dover, NH.
• ·Fitzgerald's prior roles include CFO at Potbelly Sandwich Works, President and CFO at Charming Charlie, and COO at Liz Claiborne and Bath & Body Works.
• ·Clubs located in all 50 US states, DC, Puerto Rico, Canada, Panama, Mexico, Australia, and Spain.

09-03-2026

Joshua Silverman, a Class II director of Shake Shack Inc., informed the Board on March 3, 2026, of his intention to step down after more than nine years of service, effective May 1, 2026, including from the Audit and Nominating and Corporate Governance Committees. The Board will reduce its size from nine to eight directors upon his departure, resulting in three Class I, two Class II, and three Class III directors. His decision is not due to any dispute or disagreement with the Company.

• ·Filing signed on March 9, 2026

09-03-2026

Valvoline Inc. appointed Jordan M. Denny, age 36, as Chief Accounting Officer and Controller effective March 6, 2026, succeeding Dione R. Sturgeon, who transitioned to Vice President, Treasurer and Tax. Mr. Denny, a long-time Valvoline executive with prior roles in Corporate Development, Investor Relations, Treasury, Finance, and FP&A, brings internal experience since 2013. His compensation includes an annual base salary of $319,520, 40% target incentive, and a $125,000 FY2026 equity grant (50% RSUs, 50% PSUs).

• ·Mr. Denny holds a Master of Business Administration from the University of Kentucky and is a Certified Management Accountant (CMA).
• ·No transactions required to be reported under Item 404(a) of Regulation S-K involving Mr. Denny and Valvoline.
• ·No family relationships between Mr. Denny and other Valvoline executive officers or Board members.

09-03-2026

Mesa Laboratories, Inc. (NASDAQ: MLAB) announced that Gary Owens will step down as President and CEO on April 12, 2026, after leading the company since 2017 through growth and implementation of The Mesa Way business system. Effective April 13, 2026, Dr. Siddhartha Kadia, former CEO of Calibre Scientific and with extensive life sciences experience including overseeing a $2B global business at Life Technologies, will assume the role of President and CEO and join the Board. The transition is described as smooth, with the Board highlighting Kadia's track record in scaling businesses.

• ·Gary Owens served as CEO since 2017.
• ·Dr. Siddhartha Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, M.S. from Rutgers University, and B.E. from L.D. College of Engineering, Gujarat University.
• ·Annual Report on Form 10-K referenced for year ended March 31, 2025.
• ·Contact: John Sakys, CFO, +1-303-987-8000.

09-03-2026

On March 5, 2026, Vera Therapeutics, Inc. appointed Christopher Hite to its Board of Directors as a Class III Director, with term expiring at the 2027 Annual Meeting of Stockholders. Mr. Hite received an initial nonstatutory stock option for 24,937 shares of Class A common stock at $38.85 per share, vesting monthly over three years, and a pro-rated $45,000 annual cash retainer. No related person transactions or arrangements were disclosed.

• ·Option vests monthly over three years, subject to continuous service.
• ·Future annual options vest on the earlier of one-year anniversary or next annual meeting.
• ·Mr. Hite entered into standard indemnification agreement; no arrangements or understandings for selection.

09-03-2026

On March 3, 2026, the Board of Directors of Elutia Inc. adopted the Elutia Inc. 2026 Inducement Award Plan to attract and retain new employees through equity incentives, authorizing a maximum of 2,000,000 shares of Class A common stock. The plan permits grants of stock options, restricted stock units, and other awards exclusively to individuals not previously employed by the company (or after a bona fide interruption), with no stockholder approval required. The Compensation Committee administers the plan, with standard provisions for exercise prices at 100% of fair market value and terms up to 10 years.

• ·Awards are non-transferable and subject to the company's clawback policies.
• ·In a change of control, awards may be assumed, substituted, or terminated for cash/property unless otherwise elected.
• ·No incentive stock options may be granted under the plan.

09-03-2026

Axe Compute Inc. appointed Dr. Theodore Zhu and Mr. Thorston Dirks as members of its Board of Directors on March 3, 2026. Dr. Zhu, founder of Iotelligent Technology, has a background in semiconductors including overseeing Celestial Semiconductor's $55M sale to Cavium Networks in 2011. Mr. Dirks brings 19 years of board-level experience, including CEO roles at E-Plus Group, Telefónica Deutschland, and Deutsche Glasfaser.

• ·Dr. Zhu served as Assistant Professor of Physics at Brown University and holds a Ph.D. from Purdue University.
• ·Mr. Dirks was an Executive Board Member of Deutsche Lufthansa AG and KPN N.V., and a former officer in the German Air Force.
• ·No family relationships between new directors and existing directors or executive officers.
• ·New directors' compensation consistent with Company's Director Compensation in most recent Definitive Proxy Statement.

09-03-2026

Hallador Energy Company (HNRG) appointed Daniel Hudson, a power industry veteran with over three decades of experience including $35B in energy asset transactions, to its Board of Directors effective March 6, 2026, expanding the board to seven members (six independent). The company also promoted Heath Lovell to Chief Operating Officer effective the same date, while he retains his roles as President of Hallador Power Company, LLC and Sunrise Coal, LLC. These changes align with Hallador's strategy to expand its 1 GW power generation platform at the Merom Generating Station.

• ·Daniel Hudson previously served as CEO, Chairman, and Director for power companies managing multi-gigawatt portfolios.
• ·Heath Lovell joined Hallador in 2022 from Alliance Coal, LLC and has led Indiana Coal Council, Kentucky Coal Association, and West Virginia Coal Association.

09-03-2026

Lyell Immunopharma, Inc. appointed Smital Shah as Chief Financial and Business Officer and principal financial officer effective March 9, 2026, succeeding Lynn Seely, M.D., who had served as interim principal financial officer. Ms. Shah brings extensive experience from roles at ProQR Therapeutics, Gilead Sciences, and others in biotech finance and business development. Compensation includes a $500,000 base salary, target bonus up to 50% of base, and stock options for 140,000 shares vesting 25% after one year and monthly thereafter.

• ·Event approved by Board on March 6, 2026; offer letter dated March 3, 2026.
• ·Ms. Shah provided finance and business development consulting to Lyell since February 2026.
• ·Stock option under 2021 Equity Incentive Plan; exercise price equals fair market value on grant date.
• ·Ms. Shah participates in Officer Severance Plan as Tier I Employee.
• ·Standard indemnification agreement entered with Ms. Shah.

09-03-2026

Tactile Systems Technology, Inc. (Tactile Medical) appointed Andrea Pearson to its Board of Directors, effective March 9, 2026, as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees. Ms. Pearson brings over 25 years of healthcare experience, including scaling DispatchHealth from 2 to more than 50 U.S. markets with a 30x revenue increase and growing HealthGrades' audience from 1 million monthly to 1 million daily visitors. Chairman Bill Burke highlighted her growth expertise as key to strengthening market leadership in lymphatic dysfunction and airway clearance therapies.

• ·Andrea Pearson's prior roles: Growth Advisor and Chief Marketing Officer at Harbor Health; Chief Growth Officer and Chief Marketing Officer at DispatchHealth; multiple executive roles at HealthGrades including Chief Marketing Officer and Executive Vice President and General Manager

09-03-2026

On March 6, 2026, Nobility Homes, Inc. held its annual shareholder meeting, where four director nominees were elected with overwhelming support (ranging from 2,865,944 to 2,876,490 votes for, minimal withheld votes). Shareholders voted for say-on-pay advisory votes every 3 years (2,766,714 votes) and approved the advisory resolution on 2025 executive compensation (2,880,876 votes for, only 344 against). The Board amended the 2011 Stock Incentive Plan, extending its termination date from June 1, 2026, to June 1, 2031.

• ·Votes withheld for directors: Terry E. Trexler (5,625), Thomas W. Trexler (6,050), Arthur L. Havener, Jr. (7,673), Robert P. Saltsman (16,171).
• ·Say-on-pay frequency: 2 Years (0 votes), Abstain (407).
• ·2025 executive compensation: Against (344), Abstain (895), Broker Non-Votes (0).

09-03-2026

Deluxe Corporation's Board of Directors confirmed that Director Cheryl E. Mayberry McKissack notified on March 4, 2026, that she will not stand for re-election at the Company's 2026 Annual Meeting of Shareholders. This governance update involves no changes to current board composition or operations. No financial impacts or other details were disclosed.

• ·Event reported on Form 8-K filed March 9, 2026
• ·Company address: 801 S. Marquette Ave., Minneapolis, MN 55402-2807
• ·Common stock trades as DLX on NYSE

09-03-2026

Acurx Pharmaceuticals announces a new open-label pilot clinical trial of ibezapolstat (IBZ) in up to 20 patients with multiply-recurrent C. difficile infection (rCDI), with start-up activities initiating later in March 2026 and first patient enrollment in Q4 2026, positioning IBZ for a subsequent Phase 3 registration trial. This follows Phase 2 results showing 96% clinical cure (25/26 patients) and 100% sustained cure at 1 month post-treatment (25/25 patients) with no recurrences observed. The broader CDI program is ready for Phase 3 international trials (450 subjects mITT) subject to funding, supported by FDA QIDP/Fast Track and EMA SME designations.

• ·FDA QIDP and Fast Track designations granted in 2018/2019; EMA SME designation received.
• ·Earnings call for FY/Q4 2025 results scheduled for March 13, 2026 at 8:00 am ET.
• ·University of Houston data abstract to be presented at Anaerobe Society conference July 7-10, 2026.
• ·rCDI recurrence rates: 4-19.5% post-fidaxomicin, 17-27% post-vancomycin.
• ·Phase 3 trial design: 1:1 randomized non-inferiority vs. vancomycin, 10-day oral treatment.

09-03-2026

Fortitude Life Insurance & Annuity Company (FLIAC) appointed Dan Guilbert, 52, as a Director effective March 4, 2026, with service on the Audit Committee. Mr. Guilbert brings 30 years of insurance and financial services experience, including prior roles as President of Individual Life and Retirement at Symetra Financial and Chief Actuary and Risk Officer at Hartford Life, and has been designated as an audit committee financial expert. There are no family relationships, related party transactions, or material arrangements tied to the appointment.

• ·Mr. Guilbert graduated from Bryant College with a degree in actuarial science and became a Fellow of the Society of Actuaries (FSA) in 2001.
• ·No arrangements or understandings pursuant to which Mr. Guilbert was selected as Director.

09-03-2026

On March 5, 2026, Douglas Brown informed Data I/O Corporation that he will not stand for re-election to the Board of Directors at the upcoming Annual Meeting of Shareholders, continuing to serve until the end of his current term. Mr. Brown's decision is not due to any disagreement with the company's operations, policies, or practices. The 8-K filing was signed by Charles J. DiBona, Vice President and Chief Financial Officer, on March 9, 2026.

09-03-2026

Zevra Therapeutics reported FY 2025 net revenue of $106.5 million, up 351% YoY from $23.6 million in FY 2024, primarily driven by MIPLYFFA net revenue of $87.4 million, while OLPRUVA contributed minimally at $0.8 million. Q4 2025 net revenue reached $34.1 million, a 184% YoY increase from $12.0 million and 31% QoQ growth, leading to FY net income of $83.2 million versus a $105.5 million loss in 2024. However, SG&A expenses rose 41% YoY to $77.6 million despite a 70% decline in R&D to $12.7 million.

• ·Market access for MIPLYFFA reached 68% of covered lives.
• ·EMA under review for arimoclomol MAA; 120-day questions received at year-end.
• ·8 patients enrolled in Phase 3 DiSCOVER trial in Q4 2025; recent Type C FDA meeting on acceleration.
• ·FY 2025 EPS: $1.40 basic, $1.35 diluted; Q4 EPS: $0.20 basic, $0.19 diluted.
• ·MIPLYFFA FDA approval: Sep. 20, 2024.
• ·Conference call: March 9, 2026, at 4:30 p.m. ET.

09-03-2026

Shoe Carnival, Inc. appointed Clifton E. Sifford as Interim President and Chief Executive Officer effective February 24, 2026, while he continues as Executive Vice Chairman, with compensation including an annual base salary of $1M, a monthly stipend of $2,957, a monthly automobile allowance of $1,100, and a one-time grant of 112,220 service-based RSUs vesting on March 31, 2027. The Compensation Committee approved Fiscal 2026 executive bonus targets under the EICP based on Adjusted Operating Income, with payout ranges from 25% to 175% of target (percentages of salary varying by executive), and granted service-based RSUs and PSUs to W. Kerry Jackson, Marc A. Chilton, Tanya E. Gordon, and Patrick C. Edwards. Amendments to the EICP added definitions, adjustment provisions, and extended its term by five years.

• ·Service-based RSUs for executives (except Sifford) vest 50% on March 31, 2028 and 50% on March 31, 2029.
• ·PSUs vest in full on March 31, 2029 if earned based on FY2026 adjusted net income per diluted share (25%-175% of target).
• ·J. Wayne Weaver will not participate in the EICP in Fiscal 2026.
• ·Letter Agreement dated March 5, 2026 includes non-compete, non-solicit, and non-disparagement for 12 months post-termination.

09-03-2026

AEON Biopharma, Inc. appointed John Bencich as Chief Financial Officer effective March 9, 2026 (principal financial officer effective April 1, 2026) to strengthen its executive team amid regulatory and financing milestones, with a $450,000 base salary, 40% target bonus, 754,717 RSUs, and 235,849 PSUs. The company entered into employment agreements with Bencich and Chief Accounting Officer Jennifer Sy ($275,000 base, 30% target bonus) detailing severance terms, and amended its 2025 Employment Inducement Incentive Award Plan to reserve an additional 1,000,000 shares. No prior officer departures or negative impacts were disclosed.

• ·PSUs vest starting 6 months after NYSE American compliance notification, then annually.
• ·CFO severance: 6 months base + 50% target bonus without CIC; 12 months + 100% target bonus with CIC.
• ·Chief Accounting Officer good reason resignation eligible after September 6, 2026.
• ·Bencich has 25+ years experience; CPA license held for 17 years.

09-03-2026

Sun Communities, Inc. appointed John B. McLaren, age 55 and a 24-year veteran previously serving as President since November 2024, as its new Chief Operating Officer on March 9, 2026, with an amended employment agreement featuring a $600,000 annual base salary and 150% target bonus. This follows the departure of Bruce D. Thelen from his role as Executive Vice President and Chief Operating Officer to pursue other opportunities, with no disclosed performance issues or financial impacts from the transition.

• ·Employment agreement initial term: 3 years, auto-renewing annually.
• ·Severance upon termination without cause/good reason: 1.50x (base + target bonus).
• ·Change in control payment: 2.00x (base + target bonus).
• ·Non-competition period: 3 years post-termination across U.S. and countries where Company operates.
• ·2024 Performance Vesting Shares vest based on market criteria through December 31, 2027.